Double maintains 2 strategies that include FOLD - Amicus Therapeutics, Inc.
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| IBB | 51.12% | $5.44B | 0.45% |
| XBI | 50.19% | $4.90B | 0.35% |
| BBH | 49.63% | $340.09M | 0.35% |
| PBE | 48.95% | $228.63M | 0.58% |
| FBT | 48.77% | $1.02B | 0.54% |
| PINK | 48.05% | $130.93M | 0.5% |
| FHLC | 46.60% | $2.45B | 0.084% |
| VHT | 46.06% | $15.43B | 0.09% |
| IYH | 45.94% | $2.74B | 0.39% |
| IHE | 45.83% | $559.80M | 0.39% |
| GNOM | 45.50% | $46.32M | 0.5% |
| XPH | 45.48% | $150.90M | 0.35% |
| IXJ | 44.59% | $3.76B | 0.41% |
| XLV | 43.82% | $34.49B | 0.09% |
| PPH | 41.40% | $589.08M | 0.36% |
| FXH | 41.32% | $899.37M | 0.62% |
| QUS | 40.91% | $1.60B | 0.15% |
| OUSA | 40.64% | $824.59M | 0.48% |
| USMV | 40.50% | $23.97B | 0.15% |
| HFXI | 40.40% | $1.03B | 0.2% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| IMVT | 43.33% | $2.89B | -43.13% | 0.00% |
| ROIV | 42.99% | $7.38B | +0.28% | 0.00% |
| CLPT | 42.77% | $332.40M | +78.72% | 0.00% |
| OCSL | 41.55% | - | - | 13.44% |
| BDX | 41.27% | $50.05B | -21.15% | 2.33% |
| MFA | 41.18% | $987.52M | -9.59% | 14.71% |
| LLY | 41.18% | $737.02B | -16.60% | 0.71% |
| ATXS | 41.11% | $361.74M | -37.10% | 0.00% |
| HROW | 40.75% | $1.14B | +36.01% | 0.00% |
| IRON | 39.67% | $1.83B | +12.77% | 0.00% |
| CPRX | 39.57% | $2.53B | +32.93% | 0.00% |
| ASH | 39.31% | $2.47B | -41.44% | 3.01% |
| CRH | 39.23% | $63.98B | +24.72% | 0.39% |
| CWK | 39.01% | $2.65B | +4.95% | 0.00% |
| RITM | 38.94% | $6.18B | +9.08% | 8.55% |
| GEHC | 38.94% | $34.43B | -2.17% | 0.17% |
| GPK | 38.86% | $6.66B | -12.90% | 1.90% |
| BIIB | 38.53% | $19.70B | -41.30% | 0.00% |
| WD | 38.42% | $2.47B | -23.57% | 3.63% |
| TRTX | 38.35% | $636.46M | -8.50% | 11.97% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AGL | 0.11% | $989.35M | -58.43% | 0.00% |
| CVS | -0.12% | $84.68B | +16.17% | 3.98% |
| RLMD | 0.33% | $20.25M | -85.12% | 0.00% |
| HNRG | 0.34% | $701.37M | +127.30% | 0.00% |
| LRN | 0.34% | $5.93B | +105.34% | 0.00% |
| MO | 0.40% | $100.29B | +27.49% | 6.88% |
| UPWK | 0.45% | $1.78B | +18.63% | 0.00% |
| SCKT | 0.49% | $9.51M | +8.11% | 0.00% |
| VSTA | -0.67% | $332.04M | +38.00% | 0.00% |
| ZCMD | 0.82% | $30.81M | +2.52% | 0.00% |
| CBOE | 1.06% | $24.35B | +37.95% | 1.09% |
| PRPO | 1.13% | $23.92M | +231.66% | 0.00% |
| DHT | 1.17% | $1.79B | +3.44% | 7.35% |
| OXBR | 1.21% | $15.78M | -4.50% | 0.00% |
| CYD | 1.33% | $913.95M | +160.81% | 3.69% |
| TKC | 1.48% | $5.15B | -26.86% | 5.37% |
| ASPS | 1.53% | $129.76M | +30.25% | 0.00% |
| SAVA | -1.55% | $100.48M | -81.99% | 0.00% |
| AQB | -1.55% | $3.01M | -53.91% | 0.00% |
| EQX | 1.56% | $4.46B | +1.03% | 0.00% |
Yahoo
Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 25, Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Pombiliti + Opfolda as a treatment of late-onset Pompe disease (LOPD) in adult patients. Pombiliti + Opfolda is […]
Yahoo
The United States market has experienced a 2.1% increase over the past week and is up 14% over the last year, with earnings projected to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions.
Yahoo
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in Japan for Adults with Late-onset Pompe Disease (LOPD)PRINCETON, N.J., and TOKYO, June 25, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) for the treatment of adult patients with late-onset Pompe disease (LOPD). "We are delighted that we will now be able to offer a compel
Finnhub
Amicus Therapeutics announced that Japan's Ministry of Health, Labour and Welfare has approved Pombiliti + Opfolda for the treatment of adult patients with late-onset Pompe disease . Pombiliti +...
Yahoo
Amicus Therapeutics Inc. (NASDAQ:FOLD) is one of the best biotech stocks to invest in now. On June 3, Amicus Therapeutics announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study in Muscle and Nerve. The analysis focused on the efficacy of Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) (cipa+mig) […]
SeekingAlpha
Amicus Therapeutics is growing steadily with Galafold and a promising Pompe therapy, targeting $1B revenue by 2028. See why FOLD stock is a buy.
Current Value
$6.281 Year Return
Current Value
$6.281 Year Return
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -35.40% | $185.99M | 0.85% |
| TAIL | -31.83% | $95.09M | 0.59% |
| BTAL | -19.57% | $312.42M | 1.43% |
| XHLF | -11.78% | $1.73B | 0.03% |
| FXY | -9.45% | $812.67M | 0.4% |
| TFLO | -8.94% | $6.74B | 0.15% |
| IBTF | -7.68% | $1.98B | 0.07% |
| TPMN | -6.55% | $30.94M | 0.65% |
| ULST | -6.25% | $595.49M | 0.2% |
| IVOL | -6.21% | $342.02M | 1.02% |
| FXE | -6.11% | $585.58M | 0.4% |
| KCCA | -6.04% | $108.82M | 0.87% |
| XONE | -5.70% | $627.68M | 0.03% |
| FTSD | -5.20% | $233.04M | 0.25% |
| STOT | -4.68% | $252.89M | 0.45% |
| CORN | -4.58% | $45.73M | 0.2% |
| TBLL | -3.96% | $2.12B | 0.08% |
| UDN | -3.34% | $147.89M | 0.78% |
| GBIL | -2.92% | $6.35B | 0.12% |
| CLIP | -2.65% | $1.54B | 0.07% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LITB | -12.62% | $23.17M | -74.54% | 0.00% |
| DFDV | -8.96% | $298.06M | +2,070.86% | 0.00% |
| MCK | -8.41% | $90.44B | +23.40% | 0.39% |
| NEUE | -6.69% | $60.98M | +32.62% | 0.00% |
| HUSA | -5.72% | $18.72M | -18.25% | 0.00% |
| K | -5.54% | $27.53B | +40.77% | 2.87% |
| CPSH | -5.32% | $38.93M | +59.05% | 0.00% |
| XOS | -5.01% | $27.43M | -50.75% | 0.00% |
| BTCT | -4.07% | $25.33M | +62.02% | 0.00% |
| FROG | -4.05% | $4.79B | +17.51% | 0.00% |
| SRRK | -3.22% | $3.25B | +334.52% | 0.00% |
| CNC | -3.21% | $16.22B | -50.41% | 0.00% |
| MSIF | -2.99% | $777.96M | +37.67% | 7.52% |
| AIFU | -2.94% | $15.34M | +65.63% | 0.00% |
| CARV | -2.57% | $8.88M | +17.45% | 0.00% |
| STG | -2.30% | $31.09M | -22.74% | 0.00% |
| VSA | -2.07% | $8.76M | -15.57% | 0.00% |
| LTM | -1.74% | $12.62B | -95.43% | 2.40% |
| AQB | -1.55% | $3.01M | -53.91% | 0.00% |
| SAVA | -1.55% | $100.48M | -81.99% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| WEAT | 0.22% | $124.20M | 0.28% |
| IBTG | -0.34% | $1.92B | 0.07% |
| USDU | 0.45% | $124.09M | 0.5% |
| SCHO | 0.53% | $11.00B | 0.03% |
| PSQA | 0.74% | $36.46M | 0.2% |
| BWX | -0.78% | $1.53B | 0.35% |
| IBND | 0.87% | $410.99M | 0.5% |
| IBMN | 1.38% | $445.03M | 0.18% |
| SOYB | 1.46% | $27.20M | 0.22% |
| GOVZ | -1.49% | $270.26M | 0.1% |
| UTWO | 1.75% | $376.38M | 0.15% |
| SPTS | -1.82% | $5.77B | 0.03% |
| SHV | 1.85% | $20.55B | 0.15% |
| VGSH | 2.58% | $22.64B | 0.03% |
| AGGH | 2.61% | $323.42M | 0.29% |
| CLIP | -2.65% | $1.54B | 0.07% |
| BIL | 2.76% | $41.97B | 0.1356% |
| IBTH | 2.89% | $1.61B | 0.07% |
| GBIL | -2.92% | $6.35B | 0.12% |
| CANE | 3.02% | $11.26M | 0.29% |
